ST南卫(603880) - 2021 Q4 - 年度财报

Financial Performance - The company's total revenue for 2021 was ¥527,440,662.01, representing a decrease of 50.82% compared to ¥1,072,399,917.76 in 2020[22] - The net profit attributable to shareholders for 2021 was -¥22,762,007.90, a significant decline from a profit of ¥98,067,613.55 in 2020[22] - The net cash flow from operating activities was -¥84,252,019.54, compared to ¥154,122,592.63 in the previous year, indicating a substantial decrease in operational cash generation[22] - The company's operating revenue for 2021 was CNY 527.44 million, a decrease of CNY 544.96 million compared to the previous year[31] - The net profit attributable to shareholders of the parent company was CNY -22.76 million, a decrease of CNY 120.83 million year-on-year[31] - Basic earnings per share were CNY -0.0778, down from CNY 0.3426 in 2020[24] - The weighted average return on equity was -3.42%, a decrease of 19.43 percentage points compared to 2020[24] - The company reported a gross margin of 20.71%, down 13.16 percentage points from the previous year[70] Shareholder and Governance - The company plans not to distribute profits or increase capital reserves for 2021 due to the negative net profit situation[4] - The company has a three-year shareholder return plan in place, which will be considered in future profit distribution decisions[4] - The company held 5 shareholder meetings and 12 board meetings during the reporting period to strengthen corporate governance[31] - The company emphasizes investor relations, maintaining communication with shareholders and stakeholders to protect their interests and enhance corporate value[147] - The company adheres to strict information disclosure practices, ensuring transparency and compliance with relevant regulations[148] - The company has a cash dividend policy that stipulates a minimum of 25% of distributable profits must be distributed as cash dividends when conditions allow[173] Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[7] - The company is facing risks from intensified market competition and potential changes in industry regulations that could impact its operations[132][133] - The company faces risks from changes in the overseas market environment, which may adversely affect its operations due to political, economic, and trade policy factors[134] - Fluctuations in exchange rates could impact the company's performance, particularly as export revenues are primarily settled in USD and EUR, with potential adverse effects if the RMB experiences significant volatility[135] Research and Development - The company invested CNY 30.623 million in R&D during the reporting period, a decrease of 9.83% compared to the previous year, focusing on new topical formulations and transdermal drug delivery technologies[34] - The company emphasizes technology research and development as a key competitive advantage, focusing on transdermal drug delivery technology improvements and stem cell-based tissue regeneration[59] - The company has established a "New Transdermal Preparation Research Center" in collaboration with Zhejiang University to enhance its R&D capabilities[59] - The company added 4 invention patents and 9 utility model patents during the reporting period, totaling 11 invention patents and 33 utility models[95] Product Development and Market Strategy - The company plans to expand its product line by adding a high-end medical glove production line, particularly focusing on nitrile gloves, which have shown rapid growth in the market[35] - The company is focusing on expanding its nitrile glove production capacity, which is expected to enhance market competitiveness[89] - The company is committed to improving its product offerings in the medical supplies sector, including various types of adhesive bandages and medical gloves[92] - The company is exploring the development of solvent-free medical adhesives and improving transdermal drug delivery technologies[97] Operational Efficiency - The company has a procurement model based on "sales-driven ordering," ensuring raw materials are sourced according to production orders[54] - The production model is "sales-driven production," allowing the company to adapt to customer demands and maintain service quality for large clients[55] - The company has a management team with extensive experience and a structured management system covering all operational aspects[62] - The company is committed to maintaining product quality and reducing production costs through improved procurement and supplier management[34] Environmental and Social Responsibility - The company has implemented measures to prevent water pollution, including a rainwater drainage system and proper disposal of hazardous waste[184] - The company actively engages in clean production practices and regularly maintains its environmental facilities to comply with national regulations[186] - The company has established a social responsibility management system, emphasizing a people-oriented approach and continuous improvement[188] - Employee wages have been steadily increased, with the company providing social insurance and housing funds for all employees[188] Financial Management - The company has successfully reduced its debt levels, improving its financial stability and credit rating[152] - The company is committed to optimizing its resource allocation and improving financial management to reduce costs and enhance profitability[128] - The company is seeking long-term partnerships with strategic suppliers and sales channels to build a stable production and sales integration[129] Strategic Partnerships and Acquisitions - The company is expanding its business into the cosmetics sector through a partnership with Shanghai Meilianni Cosmetics Co., transferring all related business qualifications and assets[198] - South Health Co. acquired 60% equity of Meilinni Bio from Shanghai Meilinni Cosmetics Co., with a transfer price of 12.8 million yuan based on financial status and future performance forecasts[200]